- Home
- QUBT vs XGN Comparison
QUBT vs XGN Comparison
Compare QUBT & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QUBT | XGN |
|---|---|---|
| Founded | 2001 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 138.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | QUBT | XGN |
|---|---|---|
| Price | $11.89 | $6.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $17.00 | $13.67 |
| AVG Volume (30 Days) | ★ 17.1M | 321.5K |
| Earning Date | 11-14-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $546,000.00 | ★ $63,599,000.00 |
| Revenue This Year | $135.36 | $21.76 |
| Revenue Next Year | $373.64 | $15.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 41.45 | 14.08 |
| 52 Week Low | $4.37 | $2.67 |
| 52 Week High | $25.84 | $12.23 |
Technical Indicators
Market Signals| Indicator | QUBT | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.36 | 35.96 |
| Support Level | $10.15 | $5.74 |
| Resistance Level | $12.43 | $6.21 |
| Average True Range (ATR) | 0.81 | 0.32 |
| MACD | 0.19 | 0.09 |
| Stochastic Oscillator | 72.73 | 44.34 |
Price Performance
Historical ComparisonAbout QUBT Quantum Computing Inc.
Quantum Computing Inc is an integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines to the world today. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offer capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.